| Literature DB >> 29503661 |
Amit Katiyar1, Sujata Sharma1, Tej P Singh1, Punit Kaur1.
Abstract
Women with endometriosis (EMS) appear to be at a higher risk of developing other autoimmune diseases predominantly multiple sclerosis (MS). Though EMS and MS are evidently diverse in their phenotype, they are linked by a common autoimmune condition or immunodeficiency which could play a role in the expansion of endometriosis and possibly increase the risk of developing MS in women with EMS. However, the common molecular links connecting EMS with MS are still unclear. We conducted a meta-analysis of microarray experiments focused on EMS and MS with their respective controls. The GEO2R web application discovered a total of 711 and 1516 genes that are differentially expressed across the experimental conditions in EMS and MS, respectively with 129 shared DEGs between them. The functional enrichment analysis of DEGs predicts the shared gene expression signatures as well as the overlapping biological processes likely to infer the co-occurrence of EMS with MS. Network based meta-analysis unveiled six interaction networks/crosstalks through overlapping edges between commonly dysregulated pathways of EMS and MS. The PTPN1, ERBB3, and CDH1 were observed to be the highly ranked hub genes connected with disease-related genes of both EMS and MS. Androgen receptor (AR) and nuclear factor-kB p65 (RelA) were observed to be the most enriched transcription factor in the upstream of shared down-regulated and up-regulated genes, respectively. The two disease sample sets compared through crosstalk interactions between shared pathways revealed commonly up- and down-regulated expressions of 10 immunomodulatory proteins as probable linkers between EMS and MS. This study pinpoints the number of shared genes, pathways, protein kinases, and upstream regulators that may help in the development of biomarkers for diagnosis of MS and endometriosis at the same time through improved understanding of shared molecular signatures and crosstalk.Entities:
Keywords: autoimmune disease; endometriosis; enrichment analyses; immunodeficiency; meta-analysis; multiple sclerosis; pathway analysis
Year: 2018 PMID: 29503661 PMCID: PMC5820528 DOI: 10.3389/fgene.2018.00042
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Published datasets related to endometriosis (A) and multiple sclerosis (B) used in this study.
| GPL570: [HG-U133_Plus_2] | 54675 | 20 (10/10) | Follicular phase/Ovarian-Follicular phase | Hever et al., | |
| GPL570: [HG-U133_Plus_2] | 54675 | 41 (23/18) | Follicular phase/Ovarian-Follicular phase | Unpublished | |
| GPL570: [HG-U133_Plus_2] | 54675 | 11 (05/06) | Follicular phase/Uterus-Proliferative | Burney et al., | |
| GPL570: [HG-U133_Plus_2] | 54675 | 64 (35/29) | Follicular phase/Uterus-Proliferative | Tamaresis et al., | |
| GPL96: [HG-U133A] | 22283 | 18 (09/09) | Follicular phase/Uterus-Proliferative | Hull et al., | |
| GPL570: [HG-U133_Plus_2] | 54675 | 10 (05/05) | Follicular phase/Uterus-Proliferative | Sha et al., | |
| GPL571: [HG-U133A_2] | 22277 | 22 (15/07) | Follicular phase/Uterus-Proliferative | Crispi et al., | |
| GPL570: [HG-U133_Plus_2] | 54675 | 09 (03/06) | Lutal phase/Uterus-Secretory phase (Early) | Burney et al., | |
| GPL570: [HG-U133_Plus_2] | 54675 | 30 (12/18) | Lutal phase/Uterus-Secretory phase (Early) | Tamaresis et al., | |
| GPL570: [HG-U133_Plus_2] | 54675 | 17 (08/09) | Lutal phase/Uterus-Secretory phase (Mid) | Burney et al., | |
| GPL570: [HG-U133_Plus_2] | 54675 | 50 (22/28) | Lutal phase/Uterus-Secretory phase (Mid) | Tamaresis et al., | |
| Total | 292 (147/145) | ||||
| GPL570: [HG-U133_Plus_2] | 33398 | 07 (02/05) | Brain/Early, active and late stage of MS | Han et al., | |
| GPL570: [HG-U133_Plus_2] | 54675 | 10 (04/06) | Peripheral blood/Low & high serum sema4A levels | Nakatsuji et al., | |
| GPL570: [HG-U133_Plus_2] | 54675 | 29 (15/14) | Peripheral blood/NA | Kemppinen et al., | |
| GPL6244: [HuGene-1_0-st] | 695 | 36 (12/24) | Peripheral blood/Remission & Relapse | Irizar et al., | |
| GPL570: [HG-U133_Plus_2] | 54675 | 16 (08/08) | Peripheral blood/Monozygotic twins (MZ) | Annibali et al., | |
| GPL16209: [HG Exon 1.0 ST] | 18725 | 25 (13/12) | Whole blood/Baseline | Nickles et al., | |
| GPL16209: [HG Exon 1.0 ST] | 18725 | 24 (12/12) | Whole blood/Follow-up year 1 | Nickles et al., | |
| GPL16209: [HG Exon 1.0 ST] | 18725 | 69 (28/41) | Whole blood/Baseline | Nickles et al., | |
| GPL16209: [HG Exon 1.0 ST] | 18725 | 88 (31/57) | Whole blood/Follow-up year 1/2 | Nickles et al., | |
| Total | 304 (125/179) | ||||
Figure 1Pictorial depiction of the meta-analysis (A) and enrichment analysis (B) method adopted in this study.
Top 10 differentially expressed genes identified in meta-analysis.
| 170302 | ARX | Aristaless related homeobox | 6.16 | 7.60E-16 | ||
| CLDN11 | Claudin 11 | 6.08 | 2.53E-13 | |||
| 55026 | TMEM255A | Transmembrane protein 255A | 4.66 | 8.09E-10 | ||
| 1295 | COL8A1 | Collagen type VIII alpha 1 chain | 4.49 | 2.25E-08 | ||
| 6332 | SCN7A | Sodium voltage-gated channel alpha subunit 7 | 3.92 | 2.23E-06 | ||
| NTRK2 | Neurotrophic receptor tyrosine kinase 2 | 3.54 | 5.72E-07 | |||
| 345557 | PLCXD3 | Phosphatidylinositol specific phospholipase C X domain containing 3 | 3.41 | 7.69E-09 | ||
| 23224 | SYNE2 | Spectrin repeat containing nuclear envelope protein 2 | 3.39 | 1.63E-10 | ||
| 55220 | KLHDC8A | Kelch domain containing 8A | 3.35 | 1.09E-02 | ||
| 5549 | PRELP | Proline and arginine rich end leucine rich repeat protein | 3.35 | 1.43E-04 | ||
| 115111 | SLC26A7 | Solute carrier family 26 member | −4.29 | 2.28E-08 | ||
| 56547 | MMP26 | Matrix metallopeptidase 26 | −4.25 | 3.34E-04 | ||
| 9848 | MFAP3L | Microfibril associated protein 3 | −3.75 | 1.81E-03 | ||
| CD24 | CD24 molecule | −3.42 | 2.01E-06 | |||
| 57535 | KIAA1324 | KIAA1324 | −3.42 | 3.38E-05 | ||
| 3170 | FOXA2 | Forkhead box A2 | −3.29 | 1.37E-07 | ||
| 1750 | DLX6 | Distal-less homeobox 6 | −3.20 | 7.93E-05 | ||
| 3213 | HOXB3 | Homeobox B3 | −3.19 | 1.16E-08 | ||
| 64321 | SOX17 | SRY-box 17 | −3.15 | 1.19E-05 | ||
| 27324 | TOX3 | TOX high mobility group box family member 3 | −3.10 | 2.20E-02 | ||
| 3706 | ITPKA | Inositol-trisphosphate 3-kinase A | 6.63 | 2.24E-02 | ||
| 57495 | NWD2 | NACHT and WD repeat domain containing 2 | 6.28 | 2.24E-02 | ||
| 9312 | KCNB2 | Potassium channel, voltage gated Shab related subfamily B, member 2 | 6.05 | 2.55E-02 | ||
| 9495 | AKAP5 | A kinase (PRKA) anchor protein 5 | 5.94 | 3.16E-02 | ||
| RXFP1 | Relaxin/insulin-like family peptide receptor 1 | 5.86 | 1.63E-02 | |||
| 2845 | GPR22 | G protein-coupled receptor 22 | 5.75 | 5.03E-02 | ||
| 29953 | TRHDE | Thyrotropin-releasing hormone degrading enzyme | 5.34 | 2.35E-02 | ||
| OLFM3 | Olfactomedin 3 | 5.10 | 3.26E-02 | |||
| 440279 | UNC13C | unc-13 homolog C ( | 5.08 | 2.82E-02 | ||
| 2561 | GABRB2 | Gamma-aminobutyric acid (GABA) A receptor, beta 2 | 5.05 | 2.46E-02 | ||
| 116835 | HSPA12B | Heat shock 70kD protein 12B | −15.90 | 5.19E-02 | ||
| 7276 | TTR | Transthyretin | −8.19 | 3.97E-02 | ||
| 1586 | CYP17A1 | Cytochrome P450, family 17, subfamily A, polypeptide 1 | −6.75 | 2.12E-02 | ||
| HSD3B2 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 | −6.58 | 1.36E-02 | |||
| 8788 | DLK1 | Delta-like 1 homolog (Drosophila) | −6.13 | 2.12E-02 | ||
| 53637 | S1PR5 | Sphingosine-1-phosphate receptor 5 | −5.92 | 7.78E-03 | ||
| 8513 | LIPF | Lipase F, gastric type | −5.57 | 2.24E-02 | ||
| HLA-DRB4 | Major histocompatibility complex, class II, DR beta 4 | −5.55 | 3.08E-02 | |||
| 5015 | OTX2 | Orthodenticle homeobox 2 | −5.30 | 2.06E-02 | ||
| 1584 | CYP11B1 | Cytochrome P450, family 11, subfamily B, polypeptide 1 | −5.18 | 2.61E-02 | ||
| 343450 | KCNT2 | Potassium channel, sodium activated subfamily T, member 2 | 2.71 | 4.08 | 4.15E-08 | 3.32E-02 |
| 1301 | COL11A1 | Collagen, type XI, alpha 1 | 2.60 | 4.18 | 3.49E-05 | 2.12E-02 |
| 257194 | NEGR1 | Neuronal growth regulator 1 | 2.19 | 4.32 | 1.81E-06 | 4.02E-02 |
| 27303 | RBMS3 | RNA binding motif, single stranded interacting protein 3 | 1.72 | 4.67 | 3.20E-03 | 2.06E-02 |
| LTF | Lactotransferrin | 2.39 | 3.94 | 3.18E-04 | 1.74E-07 | |
| 345557 | PLCXD3 | Phosphatidylinositol-specific phospholipase C, X domain containing 3 | 3.41 | 2.85 | 7.69E-09 | 3.51E-02 |
| BDNF | Brain-derived neurotrophic factor | 2.67 | 3.50 | 7.37E-08 | 4.29E-02 | |
| CHRM3 | Cholinergic receptor, muscarinic 3 | 1.65 | 4.37 | 3.33E-03 | 2.95E-02 | |
| 283078 | MKX | Mohawk homeobox | 3.16 | 2.82 | 2.95E-07 | 2.12E-02 |
| 2823 | GPM6A | Glycoprotein M6A | 2.10 | 3.73 | 2.11E-04 | 2.76E-02 |
| 7368 | UGT8 | UDP glycosyltransferase 8 | −2.81 | −4.30 | 2.11E-06 | 5.02E-02 |
| 6319 | SCD | WSC domain containing 2 | −1.51 | −4.68 | 6.18E-04 | 3.59E-02 |
| ERBB3 | Erb-b2 receptor tyrosine kinase 3 | −2.56 | −3.41 | 3.99E-05 | 2.11E-02 | |
| 135932 | TMEM139 | Transmembrane protein 139 | −1.72 | −3.71 | 4.39E-03 | 4.57E-02 |
| 57475 | PLEKHH1 | Pleckstrin homology domain containing, family H (with MyTH4 domain) member 1 | −1.85 | −3.57 | 6.15E-03 | 2.79E-02 |
| 6299 | SALL1 | Spalt-like transcription factor 1 | −2.35 | −2.61 | 3.81E-10 | 4.12E-02 |
| 3092 | HIP1 | Huntingtin interacting protein 1 | −2.14 | −2.73 | 6.53E-04 | 2.92E-02 |
| 4678 | NASP | Nuclear autoantigenic sperm protein (histone-binding) | −2.35 | −2.08 | 1.18E-03 | 3.68E-02 |
| 9043 | SPAG9 | Sperm associated antigen 9 | −1.53 | −2.85 | 2.98E-03 | 3.08E-02 |
| ITGB8 | Integrin, beta 8 | −1.61 | −2.73 | 1.73E-03 | 5.25E-02 | |
Bold and underlined gene IDs denoted to the existence of these genes in OMIM and DisGeNET disease databases.
p-values are adjusted, based on the False Discovery Rate (FDR) using the Benjamini–Hochberg method.
Figure 2Differentially expressed genes in the group of endometriosis vs. control and multiple sclerosis vs. control. (A) Venn diagram indicating the number of uniquely upregulated (green arrow) or downregulated (black arrow) genes compared individuals with EMS and MS to normal persons. The findings revealed 711 (32%) and 1516 (68%) genes in EMS and MS, respectively with 129 shared DEGs between them. (B) A line chart showed the occurrence of 58 (3%) and 109 (5%) genes in OMIM and DisGeNET disease databases.
Figure 3Enrichment network of shared DEGs based on biological processes. Significantly overrepresented biological processes ontology terms were analyzed and visualized by Cytoscape plugin BiNGO. The structure of GO is described in terms of a graph, where each GO term is a node, and the relationships between the terms are edges indicating parent-to-child relationships. The size of a node is proportional to the number of targets in the GO category. The color denotes enrichment significance-the deeper the color on a color scale, the higher the enrichment significance.
Figure 4Gene ontology functional analyses of DEGs. Biological significance of DEGs was documented by enriching the GO terms of biological processes. Majority of the identified DEGs, from both up-regulated and down-regulated genes were involved in inflammatory/immune responses related functions. The green, blue and red colors represent the percentage of genes, p-value and reference (p = 0.05), respectively.
Figure 5Hub genes in significant network modules. (A) The column chart shows the size of significant modules based on the number of genes they contain. Four modules, namely zero, one, two and six were found to be enriched with 25 pathways. (B) The network modules show a high degree of clustering of proteins involved in the identical disease. The hub genes with high degree and high betweenness were denoted with red color. The EMS, MS, and shared DEGs in the PPI network modules were denoted by the color yellow, green and blue, respectively. (C) The bar diagram represents the distribution of hub genes with high degree i.e., hub genes ≥ 10 nodes. The hub gene APP (amyloid beta precursor protein) was found to be connected with the highest number of neighbor's node i.e., 81 in the network.
Crosstalk interactions through overlapping edges in pathways that is significantly dysregulated (P < 0.05) in both EMS and MS.
| hsa04310 | Wnt signaling pathway | Signal transduction | 8 | 8 | 13 | Figure | |
| hsa04670 | Leukocyte transendothelial migration (a) | Immune system | 5 | 5 | 2 | Figure | |
| hsa04110 | Cell cycle | Cell growth and death | 5 | 5 | 6 | Figure | |
| hsa04114 | Oocyte meiosis | Cell growth and death | 4 | 4 | 4 | Figure | |
| hsa04666 | Fc gamma R-mediated phagocytosis | Immune system | 3 | 3 | 3 | Figure | |
| hsa04670 | Leukocyte transendothelial migration (b) | Immune system | 3 | 3 | 3 | Figure |
Genes from EMS;
genes from MS;
shared genes between EMS and MS.
ACTB, actin, beta; ANAPC4, anaphase promoting complex subunit 4; ANAPC5, anaphase promoting complex subunit 5; APC, adenomatous polyposis coli; ATM, ataxia telangiectasia mutated; CCNB1, cyclin B1; CRKL, v-crk sarcoma virus CT10 oncogene homolog (avian)-like; CTNNA3, catenin (cadherin-associated protein), alpha 3; CTNNB1, catenin (cadherin-associated protein), beta 1, 88kDa; CTNND1, catenin (cadherin-associated protein), delta 1; GAB2, GRB2-associated binding protein 2; ITGB1, integrin, beta 1; MAPK10, mitogen-activated protein kinase 10; MYL12B, myosin, light chain 12B; PIK3R1, phosphoinositide-3-kinase, regulatory subunit 1 (alpha); PSEN1, presenilin 1; PTK2, PTK2 protein tyrosine kinase 2; RAD21, RAD21 homolog (S. pombe); RPS6KA3, ribosomal protein S6 kinase, 90kDa, polypeptide 3; SOX17, SRY (sex determining region Y)-box 17; TBL1X, transducin (beta)-like 1X-linked; TBL1XR1, transducin (beta)-like 1 X-linked receptor 1; TCF7L2, transcription factor 7-like 2 (T-cell specific, HMG-box).
Figure 6Protein-protein interactions in crosstalk pathways. The results of the PPI analysis disclosed a number of interactions/crosstalk through overlapping edges in EMS and MS (shown in the figure from (A–F). The triangular symbol denoted to the DEGs from endometriosis, whereas star symbol indicated to the shared DEGs between EMS and MS. The interactions score indicates the interaction confidence between two nodes. All scores rank from 0 to 1, with 1 being the highest possible confidence. The color of edges in the PPI network correspond to the curated databases (blue), and experimentally determined (pink) from known interactions, while gene neighborhood (green), gene fusions (red), and gene co-occurrence (blue) signify predicted interactions. Further representations include text mining (yellow), co-expression (black), and protein homology (light blue).
Figure 7Subnetwork of transcription factor, intermediate protein and protein kinase. Expression2Kinases analysis of the (A) up- and (B) down-regulated genes signify the most enriched TFs and kinase from the upstream of shared DEGs based on the combined score (p-value and z-score). Node size reflects connectivity and color distinguishes transcription factors in pink, intermediate proteins in orange and kinases in blue.
Transcription factors regulating the shared up- and down-regulated genes in EMS and MS identified using Expression2Kinases (X2K).
| 1 | SOX11_23321250 | 3.70E-06 | −2.56 | 32.08 | 08 | ITGB8, PKD1L2, SALL1, SPAG9, MAP4, HIP1, MEIS1, SCD |
| 2 | AR_22383394 | 1.91E-06 | −1.53 | 20.12 | 10 ± |
| 3 | TRIM28_17542650 | 6.02E-01 | −39.13 | 19.85 | 03 | MEIS1, SALL1, ERBB3 |
| 4 | AHR_22903824 | 2.82E-04 | −2.17 | 17.76 | 05 | FNDC3B, ZKSCAN1, ANO4, CLMN, MEIS1 |
| 5 | POU5F1_16153702 | 1.90E-03 | −2.61 | 16.38 | 04 | SALL1, CDH1, SPAG9, MEIS1 |
| 6 | ARNT_22903824 | 2.08E-04 | −1.93 | 16.35 | 06 | ZKSCAN1, ANO4, CLMN, FNDC3B, SALL1, MEIS1 |
| 7 | MYCN_21190229 | 4.00E-03 | −2.86 | 15.78 | 03 | CA12, CREB5, MEIS1 |
| 8 | FOXA2_19822575 | 2.60E-06 | −1.2 | 15.44 | 12 | EPB41L2, ZKSCAN1, FNDC3B, SLC8A1, HIP1, PPP2R5E, ZAK, CDH1, RCAN1, SPAG9, PTPN11, ERBB3 |
| 9 | ELK1_19687146 | 1.01E-03 | −2.15 | 14.86 | 05 | ITGB8, SMARCC1, NASP, PTPN11, MEIS1 |
| 10 | TFAP2C_20629094 | 4.77E-04 | −1.62 | 12.39 | 06 | EPB41L2, ZKSCAN1, CLMN, FNDC3B, HIP1, PPP2R5E |
| 1 | POU3F2_20337985 | 1.76E-07 | −1.88 | 29.29 | 11 | KCND2, AKAP12, SYNE2, COL11A1, LEPR, MKX, PDZRN4, SOD2, CHL1, GPM6A, NR4A2 |
| 2 | BACH1_22875853 | 2.39E-06 | −1.89 | 24.52 | 09 | LRRC2, COL11A1, LEPR, EGR1, AKAP12, SOD2, BCL6, SYNE2, NR4A2 |
| 3 | STAT3_23295773 | 2.65E-09 | −1.13 | 22.37 | 16 | KCND2, NAMPT, BCL6, SYNE2, BDNF, CHL1, AKAP12, SORBS2, RBMS3, COL11A1, LEPR, PDZRN4, CHRM3, ITPR1, NR4A2, PLCXD3 |
| 4 | RELA_24523406 | 8.65E-06 | −1.61 | 18.74 | 08 | BDNF, EGR1, KCNT2, PER1, SOD2, NAMPT, NR4A2, LTF |
| 5 | NR3C1_21868756 | 6.16E-05 | −1.79 | 17.31 | 07 | AKAP12, SYTL2, FLRT3, FIGN, CHRM3, BCL6, GPM6A |
| 6 | TRIM28_17542650 | 6.48E-01 | −38.96 | 16.9 | 03 | KCND2, BDNF, LRRC2 |
| 7 | CTBP1_25329375 | 6.61E-05 | −1.75 | 16.84 | 07 | LRRC2, KCNT2, PDZRN4, FLRT3, CHL1, CHRM3, SYNE2 |
| 8 | CLOCK_20551151 | 5.17E-04 | −2.21 | 16.76 | 04 | ITPR1, BCL6, EGR1, PER1 |
| 9 | SMAD_19615063 | 5.94E-03 | −3.25 | 16.66 | 02 | SYTL2, BDNF |
| 10 | AHR_22903824 | 3.90E-04 | −2.1 | 16.48 | 05 | FIGN, LEPR, BCL6, MKX, NR4A2 |
TF, transcription factor;
C-score, combine score of p-value and z-score, which is used to rank the identified TFs.
Protein kinase as up- and down-regulation responsible for phosphorylation of PPI at disease state of EMS and MS.
| 1 | MAPK14 | 3.03E-03 | −2.40 | 13.91 | 05 | EPB41L2, RCAN1, SPAG9, SMARCC1, MAP4 |
| 2 | ABL2 | 1.55E-03 | −1.82 | 11.79 | 02 | PTPN11, ERBB3 |
| 3 | INSR | 7.73E-03 | −2.06 | 10.02 | 03 | EPB41L2, ERBB3, PTPN11 |
| 4 | ERBB4 | 4.56E-03 | −1.82 | 9.83 | 02 | ERBB3, PTPN11 |
| 5 | GSK3B | 9.52E-03 | −2.09 | 9.74 | 05 | CDH1, RCAN1, SMARCC1, MAP4, CLMN |
| 6 | PRKDC | 1.56E-02 | −1.85 | 7.70 | 03 | MAP4, NASP, SPAG9 |
| 7 | PTK2B | 1.24E-02 | −1.65 | 7.24 | 02 | ERBB3, PTPN11 |
| 8 | EGFR | 1.95E-02 | −1.83 | 7.21 | 03 | CDH1, ERBB3, PTPN11 |
| 9 | MAPK8 | 2.59E-02 | −1.77 | 6.45 | 03 | MAP4, NASP, SPAG9 |
| 10 | PTK2 | 2.19E-02 | −1.62 | 6.19 | 02| ERBB3, PTPN11 |
| 1 | MAPK1 | 1.69E-02 | −2.26 | 9.22 | 04 | KCND2, ITPR1, NR4A2, BCL6 |
| 2 | CSNK1D | 3.23E-02 | −1.86 | 6.40 | 02 | AKAP12, PER1 |
| 3 | PRKD3 | 2.61E-02 | −1.47 | 5.38 | 01 | BCL6 |
| 4 | WNK4 | 3.57E-02 | −1.39 | 4.63 | 01 | BCL6 |
| 5 | DDR1 | 5.78E-02 | −1.52 | 4.34 | 01 | COL11A1 |
| 6 | GRK6 | 5.47E-02 | −1.40 | 4.08 | 01 | CHRM3 |
| 7 | NTRK2 | 1.01E-01 | −1.57 | 3.61 | 01 | BDNF |
| 8 | ABL2 | 7.64E-02 | −1.39 | 3.57 | 01 | SORBS2 |
| 9 | CAMK2D | 1.13E-01 | −1.38 | 3.01 | 01 | KCND2 |
| 10 | CAMK2B | 1.04E-01 | −1.30 | 2.94 | 01 | KCND2 |
C-score, combine score of p-value and z-score, which is used to rank the identified kinase.
Figure 8Pathways crosstalk through shared components (genes and edges). The number of identified crosstalk pathways by KEGG (blue), GO: BP (red), and PPI (green and violet) methods are indicated. The top three enriched pathways based on shared genes, edges and GO terms were erbB signaling pathways, calcium signaling pathways and cell adhesion molecules.
Shared dysregulated pathways lead to endometriosis (EMS) and multiple sclerosis (MS) obtained through KEGG, GO and PPI methods.
| hsa04012 | ErbB signaling pathway | Signal transduction | 2 | 16 | 2 | 0 | 20 |
| hsa04020 | Calcium signaling pathway | Signal transduction | 4 | 16 | 0 | 0 | 20 |
| hsa04514 | Cell adhesion molecules | Signaling molecules and interaction | 7 | 13 | 0 | 0 | 20 |
| hsa04670 | Leukocyte transendothelial migration | Immune system | 0 | 12 | 0 | 5 | 17 |
| hsa04512 | ECM-receptor interaction | Signaling molecules and interaction | 0 | 17 | 0 | 0 | 17 |
| hsa04310 | Wnt signaling pathway | Signal transduction | 1 | 0 | 0 | 13 | 14 |
| hsa04110 | Cell cycle | Cell growth and death | 0 | 0 | 1 | 6 | 7 |
| hsa04114 | Oocyte meiosis | Cell growth and death | 0 | 0 | 1 | 4 | 5 |
| hsa04666 | Fc gamma R-mediated phagocytosis | Immune system | 0 | 0 | 0 | 3 | 3 |
| hsa04062 | Chemokine signaling pathway | Immune system | 0 | 2 | 1 | 0 | 3 |
| hsa04060 | Cytokine-cytokine receptor interaction | Signaling molecules and interaction | 0 | 3 | 0 | 0 | 3 |
| hsa04080 | Neuroactive ligand-receptor interaction | Signaling molecules and interaction | 0 | 3 | 0 | 0 | 3 |
| hsa04350 | TGF-beta signaling pathway | Signal transduction | 0 | 2 | 0 | 0 | 2 |
| hsa04115 | p53 signaling pathway | Cell growth and death | 0 | 0 | 1 | 0 | 1 |
KEGG, number of shared genes enriched within the common pathways of EMS and MS.
GO, number of shared genes of biological process GO terms enriched within the common pathways of EMS and MS.
PPI, number of shared genes and edges associated with the protein-protein interactions within the common pathways of EMS and MS.
Hits, the dysregulated pathways were ordered by the total number of hits.
Crosstalk interactions through shared overlapping genes or immunomodulatory proteins as probable linker in EMS and MS.
| NEGR1 | Neuronal growth regulator 1 | ↑ | ↑ | Cell adhesion molecules (CAMs) | Signaling molecules and interaction |
| LEPR | Leptin receptor | ↑ | ↑ | Cytokine-cytokine receptor interaction | Signaling molecules and interaction |
| CHRM3 | Cholinergic receptor muscarinic 3 | ↑ | ↑ | Neuroactive ligand-receptor interaction/// Calcium signaling pathway | Signaling molecules and interaction/// Signal transduction |
| ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | ↑ | ↑ | Oocyte meiosis///Calcium signaling pathway | Cell growth and death/// Signal transduction |
| SLC8A1 | Solute carrier family 8 member A1 | ↓ | ↓ | Calcium signaling pathway | Signal transduction |
| ERBB3 | Erb-b2 receptor tyrosine kinase 3 | ↓ | ↓ | Calcium signaling pathway///ErbB signaling pathway | Signal transduction |
| CDH1 | Cadherin 1 | ↓ | ↓ | Cell adhesion molecules (CAMs) | Signaling molecules and interaction |
| ITGB8 | Integrin subunit beta 8 | ↓ | ↓ | Cell adhesion molecules (CAMs)///ECM-receptor interaction | Signaling molecules and interaction |
| PTPN11 | Protein tyrosine phosphatase, non-receptor type 11 | ↓ | ↓ | Leukocyte transendothelial migration | Immune system |
| PPP2R5E | Protein phosphatase 2 regulatory subunit B'epsilon | ↓ | ↓ | Oocyte meiosis | Cell growth and death |
# Up arrow, denotes to upregulation of genes.
# Down arrow, denotes to downregulation of genes.